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Abstract  
A study was conducted among participants in an antiretroviral therapy (ART) 
clinical trial to determine how voluntary their participation was and their 
satisfaction to the consent process.  
A semi structured questionnaire was administered to 88 of the 180 people 
enrolled in the study at the time of interview and who were willing to participate.  
Participation in the study was driven mainly by unmet health needs and 
participant reported benefits (free drug and tests) as the primary motive to 
participate in the research. The absence of alternatives to access medical 
services creates challenges to voluntary participation. Most of the participants 
saw the consent process as satisfactory, the satisfaction might be based on the 
hope the treatment is giving them and on the trust they have on investigators and 
the institution. It is then of importance that research participants be given enough 
time to reflect on the information provided during the consent process before 
obtaining consent from them. 
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INTRODUCTION 
One of the core elements of informed consent (IC) is the freedom of participants to 
choose to participate in research or refuse participation without coercion. In other 
words, there should be no undue influence on the potential participant to participate. 
Beauchamp and Childress (1994) state that a person acts voluntarily to the degree that 
he or she wills the action without being under the control of another’s influence. 
However, voluntary participation in clinical trials is among the most difficult requirements 
to ensure. Pressure from a community leader, family members, the power and authority 
of the medical professionals who serve as the investigators, issues around social 
desirability, and the fear of loss of health benefits that people would normally expect to 
receive may compromise the individual’s freedom to refuse to participate in research. 
The National Bioethics Advisory Commission (NBAC) (2001) identified several barriers 
to ensuring free and individual choice to participate in research in some cultures or 
contexts. These include: deference to physician/health professional, low economic 
status of potential participants, low levels of awareness or education of potential 
participants, limited decision making power of women, community leaders disapproval 
and cultural customs that prohibit refusing a guest (rules of traditional hospitality). 
In settings with limited health care facilities and where people are poor, the reality may 
be that participation in medical research offers opportunities to have access to services 
that are not otherwise readily available. The vulnerability of the potential research 
participants’ demands that researchers take seriously their responsibility to ensure the 
rights of the participants and that participation is voluntary. 
This study describes the informed consent process in a clinical trial. How participants 
made up their mind to participate and their satisfaction with the whole consent process 
are detailed. The antiretroviral (ARV) clinical trial is a non-inferiority trial involving a new 
(generic) antiretroviral drug to be marketed within the country. At the time of study, ARV 
is available in some pharmacies in major urban cities of the country, but it costs about 
US$200 to have a complete course for a month and US$100 to have a generic. The 
cost is outside the reach of most HIV positive individuals in the country. Treatment for 
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HIV patients in the country at the time of study is mainly through the five Federal 
Government Centers that provide ARV at a subsidized rate of US$10 per month. 
METHODOLOGY 
Sample  
Eighty-eight (48.8%) of the 180 people enrolled in the clinical trial of an antiretroviral 
therapy (ART) in Nigeria participated in the study after an informed consent was 
received from them. Of the 88 respondents, 51 were female and 37 were male. The 
mean age of participants was 39.2 (range 26-62). The majorities (73) were Christians, 
and 55 were married at the time of the study. (See Table 1) 
Table 1: Demographic Characteristics of Respondents 
Demographic characteristics  No % 
Sex Male 
Female  
37 
51 
42.1 
57.9 
Employed Yes 
No  
66 
22 
75 
25 
Married  Yes 
No  
55 
33 
62.5 
37.5 
Religion  Christian 
Islam  
73 
15 
82.9 
17.1 
Education  Primary 
Secondary 
College/Technical 
University graduate 
Beyond first degree 
12 
33 
19 
22 
2 
13.6 
37.5 
21.6 
25 
2.3 
Questionnaire  
A 60-item investigator-generated semi-structured questionnaire was administered to the 
participants by the investigator and another trained interviewer. Ten of the items 
assessed voluntariness and 13 items assessed satisfaction. The investigator was not 
part of the ARV clinical trial, but was working in the Institute where the trial was being 
conducted. The questionnaire consisted of information based on the core elements of 
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informed consent, transmission of and understanding of information, the nature of 
voluntary participation and demographic characteristics of respondents. In addition, 
participants’ satisfaction with the various components of the Informed Consent process 
was assessed. These included questions about the consent form to determine the 
language of the form, its translation, their perceptions of the content, how often they 
read the form and the kind of consent obtained from them in the ARV trial. A narrative 
report of this was done. The questionnaire was pre-tested on a sample similar to the 
respondents. The interview took place two months after enrollment in the clinical trial.  
Voluntariness  
To assess voluntariness, participants were invited to describe how they decided to 
participate, who and what were involved in this decision and others influence on their 
participation. Also elicited from them was their major feeling about participation, whether 
they were hesitant at any point, how the uncertainty was resolved and the major factor 
that motivated them to participate. In order to assess voluntariness, a Likert scale of 
voluntariness was developed by researchers to assess and rate subjects' description of 
how they decided on participation and who they consulted. The ratings were done on 
two categories: pressure from others (family, researchers, and spouse) and personal 
feeling of having choice or no choice about participation. A reliability test (inter-rater) 
was applied to test the reliability of the translation. Forty of the subjects were selected to 
assess inter-rater reliability. A Spearman rank correlation was calculated for inter-rater 
reliability. The agreement was 81% for the measure of pressure from others; while the 
agreement was 89% for the measure of personal pressure, p value was significant for 
both (p<0.05). See Table 2. 
Table 2: Pressure from Others and Personal Feeling 
Pressure from Others: Family, Researchers and Spouse 
5. Subject reports extreme pressure from others to participate with threats for non-
participation 
4. Subject reports strong pressure from others to participate, but no threats 
3. Subject reports mild pressure from others to participate e.g. hopeful expectation of family 
or researchers 
2. Subject reports strong encouragement to participate, but no pressure 
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1 Subject reports mild encouragement to participate, with no pressure 
0 Subject reports no pressure or encouragement 
Personal Feeling of Having Choice about Participation 
3. Subject feels that they have no other choices, therefore have to participate because of benefits, but 
would have preferred not to participate, e.g. no chance of ART because of lack of money 
2. Subject feels that it would be wise to participate, given little or no choice, e.g. has spent much money 
on ART 
1. Subject feels that it would be an advantage to them to participate because of the benefits, even though 
there are other choices, e.g. can get ART free, and even though could afford it 
0. Subject feels no great advantage to participation, and free choice about participation  
Satisfaction 
To examine clinical trial participants satisfaction with the informed consent process, 
participants were asked to indicate on a Likert scale their level of satisfaction with the 
clarity of explanation, quality of information, utility of the consent process, effective 
response and overall satisfaction. Total satisfaction scores were also calculated.  
RESULTS  
Data were analyzed with Intercooled Stata 7.0 software. Fifty-three percent of the 
respondents indicated that someone helped them make the decision to participate in the 
study (i.e., relatives, researchers). The respondents indicated various types of advice 
given to them by these people. 
It is worthy to note that 35.2% of participants did not talk to anybody before deciding to 
participate. They felt that since the research is of direct benefit to them and HIV is a 
stigmatized disease, it was important not to talk to others about the research. One of the 
respondents said I do not need to talk to anybody about the study. I need help with this 
disease and am taking that help without discussing with anybody, once I discuss with 
others, the news that I am HIV positive will spread and this is what I have been 
avoiding.  
Respondents indicated that some of the advice they got helped them in making up their 
mind about participating or not. Responses regarding the degree of pressure 
Informed Consent in a Clinical Trial 
 
6 
experienced to participate in the study ranged from extreme pressure (9.1%) to mild 
pressure (37.5%). Responses related to encouragement ranged from strong 
encouragement (17%) to no pressure or encouragement (19.3%). One of the 
respondents said, what option do I have? I am being forced to take part in the trial by 
my family, my elder sister who I stay with said she will drive me out of the house if I do 
not enroll in the research. Another participant felt highly threatened by the counselor 
who kept mentioning the English men as sponsors and how they will remove her from 
the study if she fails to comply. Some said that they were just encouraged by the 
advice. One person that was categorized as strong encouragement said, the 
researchers told me this is the best study site where you get good treatment and 
attention; if you miss this opportunity, it might never come back to you. 
Various reasons based on personal pressure were given for why they decided to 
become part of the study. The reasons given include: have no other choice (55.6%), it is 
wise to participate (25%), participation is to my advantage (11.4%), and I have no great 
advantage to participate (8%). Most of them indicated that they joined the research 
because of the benefits and the concern they have for their health and life. One 
participant said in summary, I have spent so much on ARV and seeing a place where it 
is relatively free and with adequate check-ups mean that I have to join the research to 
enjoy such benefits considering the fact that I also do not have another option. Despite 
the fact that most of the respondents were attracted to the research because of the 
benefits, when asked if they ever considered refusing to be part of the research, 36.4% 
responded in the affirmative. The major reasons given for this consideration were those 
related to privacy/confidentiality, time to participate and personal health concerns. On 
how these uncertainties were resolved, participants considered the benefits, which they 
believed outweighed all the concerns. Some of the respondents made these 
uncertainties known to one or two members of the research team who convinced them 
that their privacy and confidentiality would be maintained. Others said that the 
researchers and also family members convinced them to participate (See Table 3). 
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Table 3: Advice Given to Respondents about Participation by Relatives and 
Researchers 
Advice  Frequency  Percentage  
It will help your life 38 43.2 
Drug is good for you 37 42.0 
It will reduce cost for you and others 33 37.5 
The study center is a good one 28 31.8 
You should participate 25 28.4 
Make sure that you enroll in the research 17 19.3 
Relative to perceived pressure from others, a one-way ANOVA revealed no significant 
difference for Christian and Islam (p =.20), male and female (p = .67), married and not 
married (p = 1.00), and employed and unemployed (p = .46). A Spearman rho indicated 
no relationship between perceived pressure from others and age (p = .745).  
Of those interviewed, 70.5% signed and 27.3% thumb printed on a consent form. All of 
the respondents indicated that they were not given a copy of the consent form. A 
member of the research team in the clinical trial explained the form prior to giving them 
the form to sign. Those who requested to read the form were given it and requested to 
sign the form after going through it. Some of the respondents (23.9%) had the form 
translated for them before signing. By this they meant that a member of the research 
team did the explanation of the contents of the form in a local language. All indicated 
that the consent form they signed was in English. Of importance is the fact that 71.6% 
said that there were things in the form they did not understand or that the explanation 
given to them was not complete. When asked what they did not understand, 23.8% 
named some technical terms especially relating to the drug, 22.3% could not remember 
what in the form they did not understand at the time of this interview, and 15.9% said 
they did not read the form and had forgotten most explanations. 
Their perception of the quality of information given to them varied. Almost half (44.3%) 
would prefer to have received more information before signing the consent form; 37.5% 
would not want more information; while 18.2% were not sure what they would want to 
know. Reasons given for not wanting more information included their interest in the drug 
and the benefits and not in information in the informed consent leaflet. Everybody 
knows that what we have is serious and anywhere one can get attention should not be 
questioned said one of the respondents. Those that would want more information would 
like it to be on the disease, drug, sponsors and everything the researchers think 
necessary for them to be knowledgeable about.  
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The time given to participants to decide on their participation ranges from 1 day to 60 
days with a mean of 13.7 days and a standard deviation of 16.77. Seventy-seven 
percent believed they were given enough time to make decisions to participate in the 
study. Though a good percentage (50%) of these made decisions the same day they 
were approached, they believed that something working for their benefits does not 
require extra time in making decisions. More than one of them said, why do I need more 
time, the drug is good for me and will help me, tests will also be done free, so what am I 
thinking about? Only twenty (22.3%) of them would have preferred more time to discuss 
the issue with others. Of this twenty, the majority (75%) said they would need between 
2-4 weeks extra time. 
The majority of the respondents said they were happy with the way information was 
given to them. (See Figure 1) 
 
Two of those that were not happy about the way information was given to them 
particularly felt threatened by the way counselors talked with them. 
The majority (69.3%) indicated they would like other types of information in addition to 
that which was given. The other information mentioned included drug reactions and 
dosages (49.1%), what happens after the trial (41%), and study design (36.1%), among 
others. 
On the question of comparative understanding at the time of the interview and when 
they entered the study, more than half of them (65.9%) said there was no difference, 
whereas, 34.1% said that there was a difference. Aspects of the trial understood 
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differently are: that they were involved in a study, the timing of study procedures and 
that they would not have access to their test results.  
It is interesting to note that 58 of the respondents indicated they were given enough 
opportunity to ask questions during the consent process, whereas 27 said they did not 
have enough opportunity. Of the former, 59.3% said the questions were not answered 
to their satisfaction. They all knew they had to come to the clinic if they had any 
complaints, as the researchers did not give any name or telephone number to contact in 
case of emergency. The seven that indicated they had a phone number said they got it 
from personal interactions with members of the research team. 
More than half of the respondents made suggestions about how researchers could 
improve the consent process. Suggestions made include, make pamphlets/posters 
(26.8%), researchers should take more time to explain research (37.5%), give 
participants enough time to go through the form and think about the research (35.7%), 
and attend to people punctually and on time (12.5%).  
As part of measure of respondent's satisfaction to the consent process, they were asked 
if they would recommend to family or friends to be part of a research study. Seventy-six 
percent responded in the affirmative, whereas, 21.6% gave a negative response. The 
majority (59.7%) of those that said yes gave benefits involved in research as a reason 
to encourage others. Nine percent of them thought that the fact the research improves 
knowledge was a good recommendation. For those that responded in the negative, a 
majority (52.6%) felt that it is the decision of the participant to make. Other reasons 
mentioned are that there are risks involved in research (31.6%), the toxicity and side 
effects of drugs (10.5%) and the distrust they have for pharmaceuticals (5.3%). 
Interestingly, only 18% of the respondents did not feel satisfied with the whole the 
consent process.  
DISCUSSION  
This study looked at the process of decision-making and participants’ satisfaction with 
the consent process of patients enrolled in a HIV clinical trial in Nigeria, Africa. Although 
participants consulted family members and researchers before making any decision 
about participation, it is interesting that in most cases, the decision to participate was 
made by the individual participant; though they considered the advice of others in this 
process. The relatives that were involved were very close relatives: mainly spouse, 
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siblings and parents. None of the participants wanted outsiders to know about their 
involvement in the research. Probably because the participants were HIV positive, and 
because the disease is often stigmatized. It might have been a different outcome if the 
research involved a less stigmatized disease. However, one cannot tell until such 
research is carried out in the country and comparison made. It can also be that research 
which is taking place in an urban center with people from diverse regions and cultures 
may reflect the changing structure and societal values that has accompanied western 
education, industrialization and urbanization, which has resulted in large-scale 
disruption of traditional patterns of life. A study undertaken for NBAC (2001) seems to 
support this view. 
Threats to autonomy can arise from the vulnerability of potential subjects as well as 
from characteristics of the researcher, the researchers’ acts and the research setting. 
Research that examines the voluntariness of decisions to participate in research is 
scanty. Hence, this scarcity may reflect the lack of a consistent method or adequate 
tools for measuring voluntariness.  
This study developed two criteria for the measurement of voluntariness (i.e. perception 
of influence from others and the subjective feeling of pressure to participate as a result 
of their personal situation). Suggested results are that family and friends can influence 
decisions to participate in research. This is done either directly by pressuring family 
members to participation, using threats for non-participation or indirectly by providing 
the necessary support and encouragement to participate. . Further, it appears as if the 
researcher’s status may influence potential participants’ willingness to participate in 
research. Several participants alluded to select research practices, which might have 
threatened the voluntariness of research participation. Faden and Beauchamp (1980) 
identified three forms of influence that may be exerted by researchers: persuasion, 
manipulation and coercion.  
Some trial participants reported pressure from researchers and family members to 
participate in the research, with some reporting very extreme pressure from family. For 
those that reported family pressure, their position in the family might be a contributing 
factor as some of them are still dependents and have to go along with family decisions.  
Two of them felt threatened by the way information was given to them by trial staff and 
participated because of fear of the researchers. We were made to understand by the 
principal investigator of the research that having counselors as research team members 
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was a later addition to the study after the importance of having them as team members 
were made known to the research team. Upon further investigation, it was observed that 
the counselors did not receive any special training at the time of this investigation even 
though it involved counseling HIV patients. This might explain the way they gave 
information to participants. Training was provided to the counselors and researchers at 
the end of this data collection.  
Some individuals might have felt compelled to participate in research because of their 
health or disease status, and/or other personal considerations. Other socio economic 
factors such as limited access to health care services may also have influenced a 
decision to enroll in research. Most clinical trial participants in this study enrolled as a 
result of the perceived research benefits, and because of having no other means of 
help. They balanced the benefit of receiving free drugs and improving their health status 
with the cost of personally financing antiretroviral therapy, and believed that 
participating in the research would benefit them and reduce the huge cost of buying 
antiretroviral on a monthly basis. The monthly cost of taking a generic ARV treatment in 
the country is about $100, and another $150 for conducting the necessary tests. Most of 
the participants could not afford to spend $100 on drugs every month. The absence of 
alternatives to access medical services creates challenges to voluntary participation. 
This study did not find any differences between gender, age, education, marriage, 
employment and occupation relative to voluntariness. Thus, no particular vulnerability 
was associated with demographic factors.  
CONCLUSIONS/RECOMMENDATIONS 
There has been a lot of debate about the amount of information that is appropriate to 
provide when seeking consent. Some have argued that it should be all the necessary 
information; while others have said it should be limited. Some trial participants in this 
study wanted a brief description, while others wanted comprehensive details. Although 
the information sheet was appreciated by them, many would have liked to take this form 
home, read it over again, digest the information properly and discuss with others. The 
authors suggest that this should be implemented during consent, as it may improve the 
consent process and participants understanding. Respondents indicated that there were 
some technical aspects of the form that they did not understand. Most of the side effects 
of the drugs were technically written and that might have explained why participants did 
not understand some of the risks involved in the study. We, therefore, recommend that 
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information sheets should be written in simple terms to aid participants’ comprehension: 
especially those with limited education. 
Our research found that clinical trial participants report they had ample opportunity to 
ask questions, which some believed were answered to their satisfaction. Overall, they 
saw the consent process as satisfactory. The only thing that may mitigate their reported 
satisfaction with the consent process is the finding that none of them had a copy of the 
consent form and 71.6% indicated that there were aspects of the consent form they did 
not understand. Most importantly, participants in this study might have reported being 
satisfied with the consent process because they saw the research as a way of meeting 
their medical and financial needs and improving the quality of life they live as HIV 
positive patients, their trust in the investigators and/or institution than on the 
comprehension of information. It is therefore our duty as researchers to be cognizant of 
the needs and motives of vulnerable groups that participate in research and to treat 
each with respect and dignity.  
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